AU2002238855B2 - N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same - Google Patents

N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same Download PDF

Info

Publication number
AU2002238855B2
AU2002238855B2 AU2002238855A AU2002238855A AU2002238855B2 AU 2002238855 B2 AU2002238855 B2 AU 2002238855B2 AU 2002238855 A AU2002238855 A AU 2002238855A AU 2002238855 A AU2002238855 A AU 2002238855A AU 2002238855 B2 AU2002238855 B2 AU 2002238855B2
Authority
AU
Australia
Prior art keywords
methyl
amino
isobutyl
acid
thiazolylsulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002238855A
Other languages
English (en)
Other versions
AU2002238855A1 (en
Inventor
Shinsuke Hashimoto
Kaoru Kobayashi
Takayuki Maruyama
Atsushi Naganawa
Yoshihiko Nakai
Tetsuji Saitoh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Publication of AU2002238855A1 publication Critical patent/AU2002238855A1/en
Application granted granted Critical
Publication of AU2002238855B2 publication Critical patent/AU2002238855B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
AU2002238855A 2001-03-12 2002-03-11 N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same Ceased AU2002238855B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2001068498 2001-03-12
JP2001-68498 2001-03-12
JP2001-281569 2001-09-17
JP2001281569 2001-09-17
JP2002007760 2002-01-16
JP2002-7760 2002-01-16
PCT/JP2002/002245 WO2002072564A1 (en) 2001-03-12 2002-03-11 N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same

Publications (2)

Publication Number Publication Date
AU2002238855A1 AU2002238855A1 (en) 2003-03-20
AU2002238855B2 true AU2002238855B2 (en) 2007-12-06

Family

ID=27346214

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002238855A Ceased AU2002238855B2 (en) 2001-03-12 2002-03-11 N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same

Country Status (24)

Country Link
US (3) US7235667B2 (enExample)
EP (2) EP1612208B1 (enExample)
JP (3) JP3555620B2 (enExample)
KR (1) KR100886854B1 (enExample)
CN (1) CN1294126C (enExample)
AT (2) ATE522513T1 (enExample)
AU (1) AU2002238855B2 (enExample)
BR (1) BR0208027A (enExample)
CA (1) CA2439604C (enExample)
CZ (1) CZ304035B6 (enExample)
DE (1) DE60220255T2 (enExample)
DK (2) DK1369419T3 (enExample)
ES (1) ES2286230T3 (enExample)
HU (1) HU230056B1 (enExample)
IL (2) IL157701A0 (enExample)
MX (1) MXPA03008134A (enExample)
NO (1) NO329682B1 (enExample)
NZ (1) NZ528120A (enExample)
PL (1) PL218750B1 (enExample)
PT (2) PT1369419E (enExample)
RU (1) RU2299202C2 (enExample)
TW (1) TWI317359B (enExample)
WO (1) WO2002072564A1 (enExample)
ZA (1) ZA200306884B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003264388A1 (en) * 2002-09-09 2004-03-29 Ono Pharmaceutical Co., Ltd. Process for producing 4-methyl-1,3-thiazol-2-ylsulfonyl halide
DK1603893T3 (da) * 2003-01-29 2008-09-08 Asterand Uk Ltd EP4 -Receptorantagonister
GB0317500D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Treatment of bph
EP1642594A1 (en) * 2003-06-27 2006-04-05 Ono Pharmaceutical Co., Ltd. Remedy for urinary tract diseases
GB0401334D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
US20080033018A1 (en) * 2004-07-05 2008-02-07 Chugai Seiyaku Kabushiki Kaisha Therapeutic Agents For Overactive Bladder
JP2008189549A (ja) * 2005-05-12 2008-08-21 Astellas Pharma Inc カルボン酸誘導体またはその塩
JP2009057282A (ja) * 2005-12-19 2009-03-19 Astellas Pharma Inc カルボン酸誘導体又はその塩
TW200817319A (en) * 2006-08-10 2008-04-16 Astellas Pharma Inc Sulfonamide compound or salt thereof
EP2123273B1 (en) 2007-02-16 2013-10-23 ONO Pharmaceutical Co., Ltd. Therapeutic agent for urinary excretion disorder
EP2177512B1 (en) * 2007-08-01 2012-04-18 Taisho Pharmaceutical Co., Ltd. Inhibitor of binding of s1p1
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
EP2305641A4 (en) * 2008-06-23 2012-08-22 Astellas Pharma Inc SULPHONAMIDE COMPOUND OR SALT THEREOF
TW201107309A (en) * 2009-07-27 2011-03-01 Kissei Pharmaceutical Indole derivatives, or the pharmaceutically acceptable salts
JP2013532688A (ja) 2010-07-26 2013-08-19 ブリストル−マイヤーズ スクイブ カンパニー Ｃｙｐ１７阻害剤として有用なスルホンアミド化合物
JP5363636B2 (ja) * 2011-10-21 2013-12-11 ファイザー・リミテッド 新規な塩および医学的使用
US20140039004A1 (en) * 2012-07-31 2014-02-06 Ono Pharmaceutical Co., Ltd. Method of treating of gastroesophageal reflux disease
PT3138633T (pt) * 2014-04-30 2019-02-01 Ind Penalver Sl Cabeça concêntrica programável para aplicação de líquido em tampas de diferentes formatos
EP3375782B1 (en) * 2015-11-13 2020-07-29 Daewoong Pharmaceutical Co., Ltd. Sodium channel blocker
RU2659955C1 (ru) * 2017-10-26 2018-07-04 Галина Ильхамовна Лукина Способ диагностики высоких гастроэзофагеальных рефлюксов

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4066636A (en) * 1976-02-02 1978-01-03 Fuji Photo Film Co., Ltd. Method of hardening gelatin
CA1032939A (en) * 1973-04-28 1978-06-13 Fujisawa Pharmaceutical Co. Sulfonic acid esters and process for preparing the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5748534B2 (enExample) * 1974-03-04 1982-10-16
DE2555048A1 (de) * 1975-12-06 1977-06-30 Pfersee Chem Fab Verfahren und vorrichtung zur herstellung bestaendiger, waessriger emulsionen wasserunloeslicher substanzen
JPH05293469A (ja) 1992-04-17 1993-11-09 Toda Constr Co Ltd 滅菌精製水の製造方法およびその装置
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
WO2000069465A1 (en) * 1999-05-12 2000-11-23 Ono Pharmaceutical Co., Ltd. Anticancer agents containing ep1 antagonists as the active ingredient
KR20020012639A (ko) 1999-07-29 2002-02-19 우에노 도시오 술폰아미드 유도체 및 알로디니아 치료제
CA2440374A1 (en) 2001-03-14 2002-09-19 Takayuki Maruyama A pharmaceutical composition for the treatment of depression comprising the ep1 antagonist as active ingredient

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1032939A (en) * 1973-04-28 1978-06-13 Fujisawa Pharmaceutical Co. Sulfonic acid esters and process for preparing the same
US4066636A (en) * 1976-02-02 1978-01-03 Fuji Photo Film Co., Ltd. Method of hardening gelatin

Also Published As

Publication number Publication date
US7629369B2 (en) 2009-12-08
JP2004149545A (ja) 2004-05-27
PT1369419E (pt) 2007-08-16
NO329682B1 (no) 2010-11-29
HUP0400155A3 (en) 2007-05-02
DE60220255D1 (de) 2007-07-05
NO20034007D0 (no) 2003-09-10
HUP0400155A2 (hu) 2004-08-30
ATE522513T1 (de) 2011-09-15
DE60220255T2 (de) 2008-01-17
US20100041708A1 (en) 2010-02-18
ATE362924T1 (de) 2007-06-15
NO20034007L (no) 2003-11-12
NZ528120A (en) 2006-05-26
CZ304035B6 (cs) 2013-08-28
DK1612208T3 (da) 2011-12-12
EP1612208B1 (en) 2011-08-31
CZ20032452A3 (cs) 2003-11-12
PL365100A1 (en) 2004-12-27
RU2299202C2 (ru) 2007-05-20
ZA200306884B (en) 2005-03-30
CN1294126C (zh) 2007-01-10
JP4432051B2 (ja) 2010-03-17
KR20030082978A (ko) 2003-10-23
EP1369419A1 (en) 2003-12-10
CA2439604C (en) 2012-05-01
JP2006028193A (ja) 2006-02-02
PL218750B1 (pl) 2015-01-30
IL157701A0 (en) 2004-03-28
US8088802B2 (en) 2012-01-03
TWI317359B (en) 2009-11-21
US20050124672A1 (en) 2005-06-09
MXPA03008134A (es) 2004-03-10
IL157701A (en) 2010-06-30
BR0208027A (pt) 2004-12-28
WO2002072564A1 (en) 2002-09-19
EP1612208A3 (en) 2006-12-06
KR100886854B1 (ko) 2009-03-05
JPWO2002072564A1 (ja) 2004-07-02
PT1612208E (pt) 2011-10-12
JP3741120B2 (ja) 2006-02-01
RU2003127677A (ru) 2005-03-27
CN1509278A (zh) 2004-06-30
US7235667B2 (en) 2007-06-26
HU230056B1 (hu) 2015-06-29
DK1369419T3 (da) 2007-09-24
US20060030713A1 (en) 2006-02-09
CA2439604A1 (en) 2002-09-19
EP1612208A2 (en) 2006-01-04
EP1369419B1 (en) 2007-05-23
ES2286230T3 (es) 2007-12-01
EP1369419A4 (en) 2005-03-16
JP3555620B2 (ja) 2004-08-18

Similar Documents

Publication Publication Date Title
US8088802B2 (en) N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation
TWI767410B (zh) 作為lpa受體拮抗劑之三唑胺基甲酸酯吡啶基磺醯胺及其用途
JP4764418B2 (ja) アルツハイマー病の治療のためのβ−セクレターゼ阻害剤として有用な２，４，６−置換ピリジル誘導体化合物
CA3079833A1 (en) Bridged bicyclic compounds as farnesoid x receptor modulators
US6900207B2 (en) N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient
WO2018008711A1 (ja) Ｅｐ４拮抗薬と免疫チェックポイント阻害薬を含んでなる組み合わせ
JP2019523237A (ja) 乳酸脱水素酵素の阻害剤としての１ｈ−ピラゾール−１−イル−チアゾールおよびそれらの使用方法
WO2008053913A1 (en) Sulfonylurea derivative capable of selectively inhibiting mmp-13
JPH10251295A (ja) テトラゾール誘導体
JP2004256473A (ja) エラスターゼ阻害活性を有する１，３，４−オキサジアゾール誘導体
ES2368334T3 (es) Compuesto de n-fenilarilsulfonamida, composición farmacéutica que comprende el compuesto como principio activo, intermedio sintético para el compuesto y procedimientos para su preparación.
AU2019265268B2 (en) Novel compound exhibiting enteropeptidase inhibitory activity
JPH09136878A (ja) テトラゾール誘導体
JPWO2001055123A1 (ja) 含窒素五員環化合物およびその化合物を有効成分とする薬剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired